[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mucositis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mucositis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,85,114,140,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100330402","phase-2-folic-acid-supplement-versus-placebo-for-treating-mucositis-adverse-events-in-metastatic-renal-cell-carcinoma-patients-receiving-targeted-therapy-100330402",false,"NCT03581773","Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy","FASTERCC: Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy. A Randomized, Double-blind Trial From the Danish Renal Cancer Group (DARENCA Study-4)","DARENCA4","Target population: Patients with inoperable, locally advanced, or metastatic renal cell carcinoma.\n\nInclusion Criteria:\n\n1. Patients displaying CTCAE ≥2 mucositis during TKI, mTOR inhibitor or immunotherapy treatment.\n2. Signed written informed consent obtained prior to any study specific procedures.\n3. Patient must be willing and able to comply with the protocol.\n4. Age ≥ 18.\n5. Biopsy proven locally advanced or metastatic renal cell carcinoma.\n6. Females with a negative serum pregnancy test unless childbearing potential can be otherwise excluded (postmenopausal, hysterectomy or oophorectomy) and not lactating.\n7. Fertile women of childbearing potential (\\\u003C2 years after last menstruation) and men must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgical sterilization).\n8. Karnofsky Performance status ≥ 60%.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to folic acid.\n2. Use of prednisolone more than 10 mg daily.",true,"ALL","18 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","FASTERCC: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy. A randomized, double-blind trial from the Danish renal cancer group (DARENCA study-4)",[28,29],"Mucositis","Stomatitis","RECRUITING","2026-04-28",{"date":33,"type":34},"2026-05-04","ACTUAL",{"date":36,"type":34},"2017-12-20",{"date":38,"type":22},"2029-09-01",{"name":40,"class":41},"Niels Fristrup","OTHER",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":65,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100488116","effect-of-a-novel-topical-composition-on-the-incidence-of-severe-oral-mucositis-in-head--neck-cancer-radiated-patients-and-quality-of-life-assessed-by-proms-100488116","NCT05635929","Effect of a Novel Topical Composition on the Incidence of Severe Oral Mucositis in Head & Neck Cancer Radiated Patients and Quality of Life Assessed by PROMs.","Effect of a Novel Topical Composition on the Incidence of Severe Oral Mucositis in Head & Neck Cancer Radiated Patients and Quality of Life Assessed by PROMs. A Two Phases Study, Part of STOP OM PROJECT. Phase 2, Single Arm, Interventional, Longitudinal, Clinical Trial.","STOPOMP","Inclusion Criteria:\n\nAcute Phase\n\n* Patients diagnosed with Head \\& Neck cancer who will undergo radiotherapy (with or without concomitant chemotherapy)\n* Patients who are able to read, understand, and complete the questionnaire.\n* Patients over 18 years of age.\n\nChronic Phase\n\n* Patients who have completed radiotherapy treatment at least 6 months before study enrollement.\n* Patients who are able to read, understand, and complete the questionnaire.\n* Patients over 18 years of age.\n\nExclusion Criteria:\n\nAcute Phase\n\n* Patients who are unable to properly use the products.\n* Patients who do not consent to participate in the study.\n* Patients who were being treated for another type of cancer.\n\nChronic Phase\n\n* Patients using medications such as pilocarpine, cevimeline, etc., to treat xerostomia.\n* Patients who do not consent to participate in the study.",{"count":52,"type":22},63,[54],"NA","The use of a novel topical mucosa composition (XCM-OM118) comprising 2-(trimethylazaniumyl) acetate; (2R,3R,4S)-pentane-1,2,3,4,5-pentol; Hexadecanoic acid; (9Z, 12Z)-octadeca-9,12-dienoic acid; octadecanoic acid; (Z)-hexadec-9-enoic acid; (Z)-octadec-9-enoic acid) delivered as a gel and a mouthwash is to be studied in regard to its effect on the incidence of severe oral mucositis in Head \\& Neck cancer radiated patients. Patient reported outcome measures seem to be an effective tool to obtain a greater knowledge of the physical and emotional state of patients, being used in this study to assess quality of life of Head \\& Neck cancer radiated patients.",[57,58,28,59,60,61,62,63,64],"Oral Mucositis","Quality of Life","Pain","Speech","Saliva","Radiation Toxicity","Chemotherapeutic Toxicity","Head and Neck Cancer",[57,66,67,59,68,69,70,71,72,64,73],"Cancer Therapy Toxic Effect","Cancer Support","Ulcers","Treatment Interruptions","Oral Mucosa","Radiotherapy","Chemotherapy","Severe Oral Mucositis","2026-04-10",{"date":76,"type":34},"2026-04-15",{"date":78,"type":34},"2022-10-11",{"date":80,"type":22},"2027-03",{"name":82,"class":83},"Mucosa Innovations, S.L.","INDUSTRY",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":19,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":94,"briefSummary":95,"conditions":96,"keywords":100,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":84},"100597090","the-effect-of-enamel-matrix-derivatives-on-gingival-tissue-thickness-100597090","NCT07053969","The Effect Of Enamel Matrix Derivatives On Gingival Tissue Thickness","The Effect Of Enamel Matrix Derivatives On Gingival Tissue Thickness. A Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Ability of subject to understand and the willingness to sign a written informed consent document.\n2. Males and females; Age 18 to 89 years old\n3. Require second stage implant uncovering\n4. In either the maxillary or mandibular arch\n5. Has consistent transportation for all clinical and study visits\n\nExclusion Criteria:\n\n1. Pregnancy, or those planning to become pregnant\n2. Allergy or any medical issue using EMD\n3. Non-English speaking\n4. Patients on anticoagulants\n5. Patients who object to the use of animal products",{"count":93,"type":22},32,[54],"Scientists do research to answer important questions which might help change or improve the way we do things in the future.\n\nThe investigators know that using Enamel Matrix Derivatives results in thicker gum tissues around teeth. This study will test to see if using EMD around implants results in thicker gum tissues around implants.",[97,98,99,28],"Dental Implantation","Missing Teeth","Periodontitis, Adult",[101,102,103,104],"Enamel Matrix Derivatives","EMD","Keratinized mucosa width","Mucosal thickness","2025-11-10",{"date":107,"type":34},"2025-11-12",{"date":109,"type":34},"2025-08-31",{"date":111,"type":22},"2027-09",{"name":113,"class":41},"The University of Texas Health Science Center at San Antonio",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":123,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100322673","phase-2-treatment-of-radiation-and-cisplatin-induced-toxicities-with-tempol-100322673","NCT03480971","Treatment of Radiation and Cisplatin Induced Toxicities with Tempol","A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy","Inclusion Criteria:\n\n1. Be ≥18 years of age with medically diagnosed squamous cell cancer of the head and neck (SCCHN);\n2. Be scheduled to receive radiotherapy or proton therapy administered with a curative intent;\n3. If female and of child bearing potential, be using an effective birth-control method with a history of reliability for the individual participant;\n4. If male and of child bearing potential, adequate methods of contraception must be employed including use of condoms with spermicide. No sperm donation for 90 days until after the conclusion of the study;\n5. Must be receiving cisplatin for chemotherapy;\n6. Be properly informed of the nature and risks of the clinical investigation, comply with all clinical investigation-related procedures, and sign an Informed Consent Form prior to entering the clinical investigation;\n7. Must have a score 2 or less on the ECOG performance status;\n8. Participant life expectancy ≥ 6 months; and\n9. Adequate baseline organ function (hematologic, liver, renal, nutritional and metabolic):\n\nHaematology:\n\nAbsolute neutrophil count (ANC) ≥1.5 Hemoglobin ≥ 10 g\u002FdL Platelets ≥ 100,000 per microliter of blood\n\nHepatic:\n\nTotal bilirubin ≤ 2 X (Upper limit normal) ULN Alanine amino transferase (ALT) and Aspartate aminotransferase (AST) ≤5 x ULN\n\nRenal:\n\nSerum creatinine ≤ ULN or, if \\> ULN calculated creatinine clearance (CrCl) ≥ 60 mL\u002Fmin.\n\nNutritional and metabolic:\n\nUrine Albumin \\\u003C 3.0 mg\u002Fdl\n\nExclusion Criteria:\n\n1. Prior radiotherapy of the head and neck;\n2. Have a clinically significant infection defined as any acute viral, bacterial or fungal infection, which requires specific therapy. Anti-infectious therapy must have been completed within 14 days of starting study treatment;\n3. Be taking any non-approved therapy for oral mucositis, including β-carotene, tocopherol, laser irradiation, brushing the oral mucosa with silver-nitrate prophylactically, systemic TGF-β (transforming growth factor beta), or systemic KGF (keratinocyte growth factor) during or within 14 days of starting treatment;\n4. Be taking mugard;\n5. Be taking prostaglandins, pentoxifylline or leucovorin during or within 14 days of starting treatment;\n6. Be rinsing with allopurinol, hydrogen peroxide, sucralfate, or chlorhexidine mouthwashes during or within 14 days of starting treatment;\n7. Have had a recent, serious, non-malignant medical complication that, in the opinion of the investigator, makes the individual unsuitable for study participation;\n8. Have used an investigational drug within 28 days of the initiation of study treatment;\n9. Have a history of a positive blood test for HIV;\n10. At the time of screening, having a significant active medical illness which, in the opinion of the investigator, would preclude completion of the study;\n11. Participants with a treatment plan consisting of chemoradiation followed by further chemotherapy;\n12. Participants with body weight less than 35 kg, 77 lbs;\n13. Women who are pregnant or who are breastfeeding;\n14. Participants with known intolerance to platin drugs;\n15. History of insulin-dependent Diabetes Mellitus; and\n16. Participants with Hepatitis B\u002FC.",{"count":122,"type":22},120,[25],"A 10 week trial to assess the ability of Tempol to prevent and\u002For reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ototoxicity will be monitored and assessed.",[28,126,127],"Nephrotoxicity","Ototoxicity",[129],"cisplatin toxicity","2024-11-18",{"date":132,"type":34},"2024-11-20",{"date":134,"type":34},"2019-05-13",{"date":136,"type":22},"2025-12",{"name":138,"class":83},"Matrix Biomed, Inc.",9,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":150,"conditions":151,"keywords":155,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":84},"100562144","effects-of-mesenchymal-stem-cell-supernatant-on-prevention-and-treatment-of-skinmucosal-injury-in-hematology-patients-100562144","NCT06599346","Effects of Mesenchymal Stem Cell Supernatant on Prevention and Treatment of Skin\u002FMucosal Injury in Hematology Patients","Study on the Effects of Mesenchymal Stem Cell Culture Supernatant on the Prevention and Treatment of Mucosal Injury in Hematology Patients","MSC-MucInj","Inclusion Criteria:\n\n* Participants aged 18 years or older.\n* Patients who have undergone hematopoietic stem cell transplantation (HSCT).\n* Patients who have developed mucosal injuries (oral, skin, or bladder) after HSCT, chemotherapy, or radiotherapy.\n* Patients who are willing to provide informed consent and comply with the study procedures.\n\nExclusion Criteria:\n\n* Patients with severe organ dysfunction (e.g., heart, liver, kidney failure) that could interfere with the study.\n* Patients with uncontrolled active infections.\n* Known allergies or hypersensitivity to MSC supernatant.\n* Pregnant or breastfeeding women.\n* Patients with HIV or active hepatitis B or C infections.\n* Patients who have participated in another clinical trial within the last 4 weeks.",{"count":122,"type":22},[54],"This clinical trial is studying the effects of mesenchymal stem cell (MSC) culture supernatant on the prevention and treatment of mucosal injuries in patients undergoing hematopoietic stem cell transplantation (HSCT). HSCT is a common treatment for blood-related cancers and other serious blood disorders. However, many patients experience severe damage to their mucous membranes, including the lining of the mouth, skin, and bladder, due to the high-dose chemotherapy used in the treatment process. These mucosal injuries can cause pain, increase the risk of infection, and lower the patient's quality of life.\n\nThe purpose of this study is to determine whether MSC culture supernatant can help repair mucosal injuries and improve recovery for these patients. MSC culture supernatant contains substances produced by mesenchymal stem cells that may promote healing and reduce inflammation. These substances could potentially repair tissue without the risks associated with using live cells.\n\nParticipants in this trial will be randomly assigned to one of two groups: one group will receive standard care, and the other will receive MSC culture supernatant as part of their treatment. The study will look at how well MSC supernatant helps heal mucosal injuries, as well as its safety and any side effects that may occur. The outcomes of this study could lead to new ways to prevent and treat mucosal injuries in patients undergoing HSCT, improving their quality of life during and after treatment.\n\nThe trial will include 120 patients who have undergone HSCT and experienced mucosal injuries. The study will last approximately five years, from October 2020 to September 2025. Participants will be monitored throughout the trial for safety and effectiveness of the treatment, with follow-up visits scheduled to assess their progress.",[28,152,153,154],"Hematopoietic Stem Cell Transplantation","Chemotherapy-Induced Mucositis","Radiation-Induced Mucositis",[156,157,158,152,72,71,159,160,161,162,163,164],"Mesenchymal Stem Cell Supernatant","Mesenchymal Stem Cell Exosomes","Mucosal Injury","Oral Mucosal Injury","Skin Mucosal Injury","Bladder Injury","HSCT Complications","Tissue Regeneration","Mucosal Repair","2024-09-14",{"date":167,"type":34},"2024-09-19",{"date":169,"type":34},"2020-10-01",{"date":171,"type":22},"2025-09-30",{"name":173,"class":41},"The General Hospital of Western Theater Command",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":17,"sex":18,"minAge":181,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":190,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":4},"100552356","assessing-manual-acupunctures-impact-on-mucositis-from-nasopharynx-cancer-radiotherapy-a-visual-analogue-scale-vas-and-quality-of-life-study-100552356","NCT06472024","Assessing Manual Acupuncture's Impact on Mucositis From Nasopharynx Cancer Radiotherapy: A Visual Analogue Scale (VAS) and Quality of Life Study","Effects Of Manual Acupuncture On Mucositis Due To Radiotherapy For Nasopharynx Cancer On Visual Analogue Scale (Vas) Score And Quality Of Life","Inclusion Criteria:\n\n* Subjects who have been proven by anatomical pathology examination to have a diagnosis of Nasopharyngeal Cancer.\n* Subjects with adult Nasopharyngeal Cancer aged 19 years - 59 years.\n* Nasopharyngeal Cancer Patients, who underwent bilateral Head and Neck radiotherapy.\n* Patients diagnosed with mucositis.\n* Willing to participate in the research until completion by signing an informed consent.\n\nExclusion Criteria:\n\n* Nasopharyngeal Cancer patients who have distant metastases (based on the Tumor Node Metastasis (TNM) classification with the presence of metastases (M1)).\n* Subjects who still smoke and consume alcohol to date.\n* Patients have contraindications for manual acupuncture, namely the use of anti-coagulant drugs, the presence of infection or wounds at the puncture site, emergency conditions, and pregnancy.\n* There is a history of allergy to stainless steel materials.\n* Patients with blood clotting disorders; Platelets \\\u003C50,000\u002FμL, Absolute Neutrophil Count (ANC) \\\u003C1000\u002Fmm3, patients undergoing anticoagulant therapy with International Normalized Ratio (INR) \\>2.47","19 Years","59 Years",{"count":184,"type":22},30,[54],"The goal of this clinical trial is to learn if acupuncture can play a role in reducing pain and improving the quality of life of post-radiotherapy nasopharyngeal cancer mucositis patients. The main questions it aims to answer are:\n\n\\- Do manual acupuncture and medication therapy affect pain intensity as measured by the visual analogue scale (VAS) in patients with oral mucositis compared with sham manual acupuncture and medication?\n\nParticipants will receive acupuncture therapy 2 times a week for 3 weeks",[188,189,28],"Cancer","Nasopharyngeal Carcinoma","NOT_YET_RECRUITING","2024-06-24",{"date":193,"type":34},"2024-06-26",{"date":195,"type":22},"2024-07",{"date":197,"type":22},"2024-09",{"name":199,"class":41},"Indonesia University"]